'SELF' starter

Connective Therapeutics (CNCT) and Palladin Group, with the assistance of AFO Capital Advisors LLC, structured a financing deal that guarantees CNCT with access to a buyer for up to $25 million worth of CNCT stock. The agreement - termed a Structured Equity Line Flexible Financing Agreement, or "SELF" Financing - essentially gives the Palo Alto, Calif., company a "put" to sell up to $25 million to Palladin in tranches of

Read the full 709 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE